NDAORALTABLET
Approved
Jul 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
CELEXA (citalopram) by AbbVie is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for major depressive disorder. First approved in 1998.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELEXA (citalopram) is an oral selective serotonin reuptake inhibitor (SSRI) approved in 1998 for major depressive disorder and generalized anxiety disorder. It works by inhibiting neuronal reuptake of serotonin in the central nervous system, though its exact mechanism remains incompletely understood. Off-label use extends across multiple psychiatric and medical conditions including treatment-resistant depression, bipolar disorder, insomnia, and hot flashes.
$3MPart D
LOE ApproachingDeclining
Mature product with low Part D utilization signals a shrinking franchise requiring defensive positioning as generic penetration increases.
Mechanism of Action
unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications (1)
Clinical Trials (20)
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Started Apr 2026
186 enrolled
Major Depressive DisorderMild Neurocognitive DisorderHIV
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Started Mar 2021
132 enrolled
Anxiety
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
Started Oct 2020
0Major Depressive Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Started May 2019
273 enrolled
Anxiety Disorders,Generalized Anxiety Disorder
A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects
Started Apr 2019
24 enrolled
Healthy
Worked on CELEXA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.